Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.47 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31040490 | 1.00 | ALDH1A1 (0.49) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL31040491 | 1.00 | ALDH1A1 (0.49) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL28255049 | 0.91 | HDAC1 (0.48) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL15777571 | 0.89 | EHMT2 (0.48) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL844408 | 0.88 | EHMT2 (0.47) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL15669431 | 0.87 | EHMT2 (0.46) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL17253259 | 0.87 | LMNA (0.47) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL20863126 | 0.84 | ALDH1A1 (0.64) | ALDH1A1MAPTKMT2ALMNAHPGD | |
| SCHEMBL2738375 | 0.84 | LMNA (0.51) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL20095020 | 0.84 | LMNA (0.45) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117545475-A | Brain-targeted antibody nanoparticles for treatment of neurodegenerative diseases | 南卡罗来纳大学 | 2024-02-09 | — | — | CN | claimed |
| WO-2022235329-A1 | BRAIN-TARGETED ANTIBODY NANOPARTICLE FOR NEURODEGENERATIVE DISEASES THERAPY | UNIVERSITY OF SOUTH CAROLINA (US) | 2022-11-10 | — | — | WO | claimed |
| US-11478493-B2 | Fabrication and application of a hetero-targeted nano-cocktail with traceless linkers | UNIVERSITY OF SOUTH CAROLINA (US) | 2022-10-25 | — | — | US | claimed |
| US-20200281955-A1 | Fabrication and Application of a Hetero-Targeted Nano-Cocktail with Traceless Linkers | UNIVERSITY OF SOUTH CAROLINA | 2020-09-10 | — | — | US | claimed |
| US-10221271-B2 | Polymer/copper combination for targeted cancer therapy | UNIVERSITY OF SOUTH CAROLINA (US) | 2019-03-05 | — | — | US | claimed |
| US-20180037687-A1 | Polymer/Copper Combination for Targeted Cancer Therapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-08 | — | — | US | claimed |
| US-9861704-B2 | Polymeric prodrug of disulfiram and application thereof | UNIVERSITY OF SOUTH CAROLINA (US) | 2018-01-09 | — | — | US | claimed |
| US-9822202-B2 | Polymer/copper combination for targeted cancer therapy | UNIVERSITY OF SOUTH CAROLINA (US) | 2017-11-21 | — | — | US | claimed |
| EP-1789391-B1 | BIVALENT LINKERS AND CONJUGATES THEREOF | ENDOCYTE INC (US) | 2017-06-28 | — | — | EP | claimed |
| US-20160346208-A1 | DUAL RESPONSIVE BRAIN TARGETED NANOPARTICLES AND THEIR APPLICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-01 | — | — | US | claimed |
| US-20160166706-A1 | Polymeric Prodrug of Disulfiram and Application Thereof | UNIVERSITY OF SOUTH CAROLINA | 2016-06-16 | — | — | US | claimed |
| US-20240058478-A1 | FOLATE RECEPTOR-TARGETED CONJUGATES, COMPOSITIONS, AND DELIVERY TO THE CENTRAL NERVOUS SYSTEM | PURDUE RESEARCH FOUNDATION | 2024-02-22 | — | — | US | disclosed |
| CN-117545475-A | Brain-targeted antibody nanoparticles for treatment of neurodegenerative diseases | 南卡罗来纳大学 | 2024-02-09 | — | — | CN | disclosed |
| US-20240033240-A1 | DUAL RESPONSIVE BRAIN TARGETED NANOPARTICLES FOR USE IN TREATMENT OF ALZHEIMER'S DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-01 | — | — | US | disclosed |
| CN-117337190-A | Folate receptor targeted conjugates, compositions and delivery to the central nervous system | 普渡研究基金会 | 2024-01-02 | — | — | CN | disclosed |
| EP-2515651-A1 | VITAMIN RECEPTOR DRUG DELIVERY CONJUGATES FOR TREATING INFLAMMATION | Endocyte, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120258905-A1 | VITAMIN RECEPTOR DRUG DELIVERY CONJUGATES FOR TREATING INFLAMMATION | ENDOCYTE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| WO-2012047525-A2 | FOLATE CONJUGATES FOR TREATING INFLAMMATION OF THE EYE | ENDOCYTE, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012044832-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | FETZER OLIVER S (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011063421-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258905-A1 | VITAMIN RECEPTOR DRUG DELIVERY CONJUGATES FOR TREATING INFLAMMATION | VDR, HCAR1, CYP2R1 | ALDH1A1 885/4885EHMT2 3030/4885EHMT1 3519/4885 |
| US-20160346208-A1 | DUAL RESPONSIVE BRAIN TARGETED NANOPARTICLES AND THEIR APPLICATIONS | DUOX2, DUOX1, VEGFA | ALDH1A1 1087/4885EHMT2 3060/4885EHMT1 4145/4885 |
| US-20160166706-A1 | Polymeric Prodrug of Disulfiram and Application Thereof | P4HB, PDIA6, CD44 | ALDH1A1 18/4885EHMT2 2785/4885EHMT1 2867/4885 |
| US-20180037687-A1 | Polymer/Copper Combination for Targeted Cancer Therapy | PDIA6, P4HB, MPST | ALDH1A1 236/4885EHMT2 2122/4885EHMT1 3580/4885 |
| US-20240033240-A1 | DUAL RESPONSIVE BRAIN TARGETED NANOPARTICLES FOR USE IN TREATMENT OF ALZHEIMER'S DISEASE | DUOX2, DUOX1, PDE1A | ALDH1A1 1027/4885EHMT2 2522/4885EHMT1 3593/4885 |
| US-10221271-B2 | Polymer/copper combination for targeted cancer therapy | PDIA6, P4HB, MPST | ALDH1A1 236/4885EHMT2 2122/4885EHMT1 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.